These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36306996)

  • 1. PROTACting the kinome with covalent warheads.
    Chatterjee DR; Kapoor S; Jain M; Das R; Chowdhury MG; Shard A
    Drug Discov Today; 2023 Jan; 28(1):103417. PubMed ID: 36306996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide-based PROTACs: Current Challenges and Future Perspectives.
    Wang H; Chen M; Zhang X; Xie S; Qin J; Li J
    Curr Med Chem; 2024; 31(2):208-222. PubMed ID: 36718000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteolysis-targeting chimeras: A promising technique in cancer therapy for gaining insights into tumor development.
    Lv M; Hu W; Zhang S; He L; Hu C; Yang S
    Cancer Lett; 2022 Jul; 539():215716. PubMed ID: 35500825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
    Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
    Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PROTAC-DB 2.0: an updated database of PROTACs.
    Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
    Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expanding role for small molecules in immuno-oncology.
    Offringa R; Kötzner L; Huck B; Urbahns K
    Nat Rev Drug Discov; 2022 Nov; 21(11):821-840. PubMed ID: 35982333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PROTACs to address the challenges facing small molecule inhibitors.
    Martín-Acosta P; Xiao X
    Eur J Med Chem; 2021 Jan; 210():112993. PubMed ID: 33189436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PROTACs technology for targeting non-oncoproteins: Advances and perspectives.
    Wang C; Zhang Y; Xing D; Zhang R
    Bioorg Chem; 2021 Sep; 114():105109. PubMed ID: 34175722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
    Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
    BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
    Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
    Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of reversible and irreversible covalent chemistry in targeted protein degradation.
    Kiely-Collins H; Winter GE; Bernardes GJL
    Cell Chem Biol; 2021 Jul; 28(7):952-968. PubMed ID: 33789091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
    Ishida T; Ciulli A
    SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Frontiers in the Discovery and Development of PROTACs.
    Barghout SH
    Anticancer Agents Med Chem; 2022 Aug; 22(15):2656-2661. PubMed ID: 35418290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras.
    Wang Y; Han L; Liu F; Yang F; Jiang X; Sun H; Feng F; Xue J; Liu W
    Colloids Surf B Biointerfaces; 2020 Apr; 188():110795. PubMed ID: 31991291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing PROteolysis TArgeting Chimeras (PROTACs) for hematologic malignancies.
    Wu Y; Zhang J; Zhu X; Zhang Y
    Cancer Lett; 2022 Sep; 544():215808. PubMed ID: 35764266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
    Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
    Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
    Gu S; Cui D; Chen X; Xiong X; Zhao Y
    Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
    He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Undruggable Transcription Factors with PROTACs: Advances and Perspectives.
    Li Y; Song J; Zhou P; Zhou J; Xie S
    J Med Chem; 2022 Aug; 65(15):10183-10194. PubMed ID: 35881047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy.
    Yuan M; Chu Y; Duan Y
    Front Chem; 2021; 9():691093. PubMed ID: 34291036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.